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Inhibition of Ras-stimulating enzymes is a possible avenue to treat Ras-driven diseases. In this issue
of Chemistry & Biology, Evelyn and coworkers report an inhibitor for one such enzyme, Sos1, capable of
impairing wild-type Ras signaling in cells.H-, K-, and N-Ras toggle between ‘‘off’’
(GDP-bound) and ‘‘on’’ (GTP-bound)
states during signal transduction. This
cycle is controlled by guanine exchange
factors (GEFs) and GTPase-activating
proteins (GAPs) that catalyze the stimula-
tion (Figure 1A, point a) and inactivation
(Figure 1A, point b) of Ras proteins,
respectively. GTP-bound Ras proteins
bind to phosphatidylinositol 3-kinase a
(PI3Ka), Raf kinases, and other effectors,
leading to signaling diversification and
amplification events in stimulated cells.
This regulation is broken by mutations
that generate oncogenic proteins defi-
cient in GTP hydrolysis, overexpression
of wild-type Ras (RasWT) proteins, inacti-
vation of GAP-encoding genes, or de-
regulated upstream signaling elements
(Figure 1A). Due to their frequent occur-
rence in human tumors, most drug dis-
covery efforts have focused on mutant
Ras (RasMUT) proteins and key down-
stream elements (Stephen et al., 2014).
However, for pathologies exhibiting high
amounts of RasWT signaling, targeting
wild-type GTPases could be a therapeuti-
cally interesting option. The spectrum
of RasWT-dependent diseases might be
even larger than currently appreciated,
because recent reports have unveiled
key roles for H- and N-RasWT in RasMUT-
driven tumorigenesis. Such functions
include the generation of outbursts of
Raf and PI3Ka signaling in mitogen-stim-
ulated cancer cells (Figure 1A, point c)
(Young et al., 2013), the dampening of
K-RasMUT signals to avoid activation of
the DNA damage response (Figure 1A,
point d) (Grabocka et al., 2014), and,
possibly the engagement of nonover-
lapping effectors (Figure 1A, point e)
(Stephen et al., 2014). RasWT proteins
are also implicated in signaling compen-satory effects elicited by anti-Ras thera-
pies, such as the stimulation of Ras
pathways caused by the loss of the
MEK-mediated inhibition of the EGF
receptor typically observed when using
MEK inhibitors (Figure 1A, point f) (Young
et al., 2013). An inference from these
studies is that inhibitors of the Ras GDP/
GTP exchange reaction can represent,
either singlehandedly or combined with
other treatments, a potential therapeutic
avenue for diseases featuring deregulated
Ras activity. Up to now, the search
for such inhibitors has been focused
on Ras-binding compounds promoting
GTPase conformations incompatible with
GEF interactions. This approach has led
to the isolation of compound families
that recognize pockets located in the
vicinity of the two Ras switch domains,
the regions that mediate the Ras-GEF
interaction. However, these molecules
lack commercial interest because of
low potency and inappropriate pharma-
cochemical features (Wang et al., 2012).
Given that these molecules have to
interact at 1:1 ratios with Ras proteins
to promote noticeable inhibitory effects,
it is unlikely that this strategy will yield
drugs with good therapeutic indexes.
A more efficient alternative might be
the use of drugs against the catalytic ac-
tivity of Sos1, the Ras GEF in charge of
stimulating RasWT proteins downstream
of most receptors, RasMUT GTPases,
and oncogenic protein tyrosine kinases
(Jeng et al., 2012; Qian et al., 2000).
This GEF is regulated by both receptor-
mediated plasma membrane tethering
steps (Figure 1A, point g) and an allosteric
effect induced by the binding of active
Ras molecules to a regulatory Sos1
domain (Figure 1A, h points) (Cherfils
and Zeghouf, 2013). In this issue ofChemistry & Biology 21, December 18, 2014Chemistry & Biology, Evelyn et al. (2014)
report the in silico screen-based isolation
of an inhibitor (NSC658497) directed
against a structural pocket located in the
Sos1 catalytic domain (Figure 1B, site a).
This site was a good pick in hindsight,
because the binding of chemicals to a
second Sos1 pocket causes increased
catalytic rates (Burns et al., 2014) (Figure
1B, site b). As expected, NSC658497
blocks the interaction of Sos1 with RasWT
proteins, Sos1 enzyme activity, and Ras
signaling in both mitogen-stimulated and
hyperactive Sos1 mutant-expressing
cells. Although not tested, the in vivo ef-
fects of the inhibitor are probably medi-
ated by the concurrent inactivation of
the highly related Sos2 protein. This com-
pound cannot bind to versions of the
Sos1 catalytic domain carrying mutations
in the putative drug-binding site, thus
confirming its mechanism of action. In
contrast to earlier data using Sos1- and
RasWT-depleted cells (Grabocka et al.,
2014; Jeng et al., 2012), Evelyn et al.
(2014) find no overt effect of NSC658497
in the fitness of K-RasMUT-expressing
cancer cells. This suggests that the inhib-
itor may not have enough potency to
block the K-RasMUT-mediated allosteric
activation of Sos1 (Jeng et al., 2012) or,
alternatively, that the K-RasMUT cell lines
utilized in the present study stimulate
RasWT proteins using GEF-independent
mechanisms. To clarify this discordance,
it would be important to investigate
the effect of NSC658497 in the Sos1-
and RasWT-dependent cancer cell lines
used in previous studies (Grabocka
et al., 2014; Jeng et al., 2012), expand
these analyses to larger numbers of
RasMUT-expressing cancer cells, and
verify whether the K-RasMUT-express-
ing cell lines used in the present workª2014 Elsevier Ltd All rights reserved 1599
Figure 1. Therapeutic Targeting of Sos1 in Ras-Dependent Diseases
(A) Ras regulatory cycle and Sos1-mediated crosstalk established between
RasWT- (green) and K-RasMUT-regulated (red) pathways. Red asterisks indi-
cate genetic alterations that lead to the spurious activation of RasWT proteins.
Other signaling crosstalk are not shown for the sake of simplicity. PTK, protein
tyrosine kinase (membrane anchored or cytosolic).
(B) Binding sites of inhibitory (site a, red) and stimulatory (site b, brown) com-
pounds of Sos1 enzyme activity in one of the subregions of the Sos1 catalytic
site. Sos1 residues potentially involved in the interaction with these com-
pounds are shown in stick form and labeled. The Ras switch II region is shown
in blue. The Sos1 aH helix that gets into a cleft between the switch regions and
that is critical for the exchange reaction is not shown. N and C, N- and C-
termini of the Sos1 fragment shown.
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dent. Other therapeutically-
interesting studies to carry
out in the near future include
the analysis of NSC658497
in protein tyrosine kinase-
dependent transformation
processes (Qian et al.,
2000), its synergism with
currently available anti-Ras
pathway drugs (Young et al.,
2013), and validation in ani-
mal models. Tackling these
issues will help foresee
the pharmacological poten-
tial and spectrum of appli-
cations of this inhibitor and
subsequent derivatives.
The therapeutic viability of
this avenue has yet to be
explored. The potency of
NSC658497 is low in cells,
indicating that further optimi-
zation steps will be needed.
The eventual applicability of
these compounds will also
depend on in vivo pharmaco-
kinetic behavior, therapeutic
efficacy, toxicity, and side
effects directly derived from
the inactivation of Sos pro-
teins in healthy tissues. The
latter problem requires spe-
cial attention here, because
genetic analyses indicate
that the concurrent inactiva-
tion of Sos1 and Sos2 causes
lethal effects in adult mice
(Baltana´s et al., 2013). These
problems should not occur
when using Sos1-specific
inhibitors, as inferred by
the viability shown by mice
lacking Sos1 in postnatal pe-
riods (Baltana´s et al., 2013).1600 Chemistry & Biology 21, December 18, 2014 ª2014 Elsevier Ltd All rights reservedRegardless of these potential
caveats, this work highlights
the feasibility of isolating
Ras GEF-specific inhibitors,
opens the door to new thera-
peutic opportunities in Sos-
dependent diseases, and pro-
vides a valuable tool to further
address Sos function in cells.
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